WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Kevin D. FreemanDirector2024-04-222,500$2.98
$7.45kBuy
Joel LewisPresident and CEO2024-03-01152,584$1.96
$299.06kSell
Richard E. UihleinDirector2024-01-2423,256$1.72
$40.00kBuy
Kary EldredDirector2024-01-16500$1.79
$893.00Buy
Joel LewisPresident and CEO2023-12-2911,606$1.66
$19.27kBuy
Joel LewisPresident and CEO2023-12-1512,042$1.60
$19.27kBuy
Joel LewisPresident and CEO2023-11-309,880$1.95
$19.27kBuy
Joel LewisPresident and CEO2023-11-1510,303$1.87
$19.27kBuy
Joel LewisPresident and CEO2023-10-319,444$2.04
$19.27kBuy
Joel LewisPresident and CEO2023-10-139,585$2.01
$19.27kBuy

1 of 3

GALT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP41.60%25,751,845$87.04MInsider
James C. Czirr28.65%17,732,569$59.94MInsider
Rod D. Martin19.48%12,057,197$40.75MInsider
Richard E. Uihlein16.63%10,296,461$34.80MInsider
David Platt13.60%8,418,743$28.46MInsider
Vanguard Group Inc3.14%1,941,854$6.56MInstitution
Osaic Holdings Inc2.02%1,251,048$4.23MInstitution
Joel Lewis1.45%898,716$3.04MInsider
Blackrock Inc1.16%715,351$2.42MInstitution
Geode Capital Management LLC0.83%514,416$1.74MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT8.66%91.34%Net BuyingNet Selling
CMPX62.59%12.24%Net BuyingNet Selling
DSGN42.98%57.02%Net BuyingNet Buying
TELO0.00%16.90%Net BuyingNet Buying
OPT1.53%0.00%
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 11.67% institutional shareholders, 122.98% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 25.75M shares representing 41.60% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $84.72M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.